.png)
Post-traumatic stress disorder (PTSD) remains a significant leadership challenge in behavioral health, with ongoing gaps in addressing its dual psychological and biological roots. Bridging these is vital for better outcomes.
Approximately 70% of adults in the United States experience trauma, which can result in sleep disturbances, irritability, impaired interpersonal relationships, absenteeism, and increased medical expenses ("Post-Traumatic Stress Disorder (PTSD)", 2023). In high-stress sectors such as law enforcement, organizational costs are substantial; for example, replacing an experienced officer may cost nearly $190,000 (Klein, 2023). Trauma constitutes both a public health and workforce challenge.
This strategic shift in trauma care raises another essential question: Why is a focus on biology so critical to progress?
For decades, behavioral health has treated the mind and body as separate entities. But research in psychoneuroimmunology has made the link undeniable (McCain, 1994). Trauma doesn’t just alter memory and mood; it changes immune function, hormone regulation, and brain structure.
When stress is severe or prolonged, the fight-or-flight system can remain activated. This prolonged response drives chronic inflammation in the body and brain. People with PTSD often show elevated cytokines, proteins like IL-1β, IL-6, and TNF-α, that weaken the blood–brain barrier and promote neuroinflammation (Passos, 2015). These changes affect regions that regulate memory, mood, and threat perception, thereby fueling symptoms such as hypervigilance, low mood, difficulty concentrating, headaches, and irritability.
Individual responses to trauma vary considerably. Some individuals recover rapidly, while others experience persistent biological stress that increases the risk of relapse. Achieving sustainable recovery requires addressing both psychological experiences and biological restoration to provide comprehensive care.
PTSD exhibits considerable heterogeneity in symptom presentation, including re-experiencing traumatic events, avoidance behaviors, mood alterations, and hyperarousal. Factors such as genetics, personal history, culture, and environment influence individual experiences of trauma. This complexity underscores the necessity for objective assessment measures.
Biomarkers, defined as biological indicators of stress and inflammation, provide a novel framework for guiding trauma care:
An example of this approach is the Trauma Autoimmune Indicator (TAI™) test, developed by iXpressGenes. This blood test evaluates immune function, oxidative stress, and alterations in the blood-brain barrier ("Trauma Autoimmune Indicator (TAI) Screening", n.d.). The test is designed to translate complex biological data into actionable insights that clinicians can integrate with patient-reported symptoms.
Biomarkers are not intended to replace therapeutic interventions. Instead, they enhance clinical practice by providing additional information to guide intervention timing, adjust treatment strategies, and monitor patient progress.
Health practitioners have long utilized established therapies, including Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR). These interventions are supported by clinical guidelines as effective for a broad range of patients. Pharmacological interventions, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), further augment therapeutic outcomes.
However, despite the efficacy of these interventions, barriers such as limited access, high dropout rates, and inadequate cultural adaptation persist in behavioral healthcare. Treatment effectiveness is compromised when patients are unable to initiate or maintain engagement. Integrating technological innovations and biological research offers an opportunity to address these limitations. For example, combining trauma-focused therapy with biomarker-informed monitoring enables clinicians to assess physiological stress responses in real time and utilize genetic information to individualize pharmacological interventions, thereby enhancing treatment efficacy.
The behavioral health technology sector is undergoing rapid development, resulting in several notable innovations:
Digital interventions, when integrated with advances in biological research, contribute to a comprehensive model of trauma care that addresses psychological and physiological dimensions. The future of trauma care is likely to be characterized by an integrated approach that incorporates digital technologies and biological insights.
Diagnostic tools are effective only when integrated with comprehensive care systems. The collaboration between Blue Rose and iXpressGenes exemplifies such integration.
Blue Rose has decades of experience serving military families, first responders, and other high-risk groups. Its clinicians have supported non-medical counseling at hundreds of military installations and partnered with the National Guard Bureau on resilience programs. When paired with tools like the TAI™ test, these services can identify stress earlier and connect people to interventions before problems escalate.
Healthcare systems, employers, and policymakers must drive progress by integrating diagnostic tools with comprehensive care systems. Prioritizing data-driven resource allocation ensures robust counseling provision and maintains continuity of care across organizational boundaries.
The Economics of Prevention in the Workplace
Healthcare and organizational leaders should be aware that untreated trauma leads to persistent symptoms, impaired team performance, and rising costs, from absenteeism to turnover. Allowing crises to dictate action is inefficient and costly.
Research shows proactive wellness programs reduce sick leave, workers’ compensation claims, and improve retention (Smith, 2011; Pokrzywa, 2015). For high-stress sectors, this can mean significant financial savings.
Employers and policymakers implementing biomarker-guided strategies can enhance prevention. Early identification enables efficient resource use, sustained readiness, and lowers the costs and disruption of crisis interventions. Prevention is a strategic imperative.
Leaders should anticipate obstacles to innovative PTSD care. To succeed, leaders across healthcare, government, and industry must address:
To move the field forward, healthcare systems, employers, and policymakers must develop models that integrate biological and psychological approaches, prioritize prevention, and ensure equitable access to care.
The objective is not to reduce trauma care to quantitative data or to substitute human care with technology. Rather, the aim is to expand available tools by integrating scientific, technological, and compassionate approaches, thereby shifting care from crisis response to proactive and precise recovery.
The partnership between Blue Rose and iXpressGenes is one example of what’s possible: pairing objective biological insights with trauma-informed, culturally sensitive care. But many more efforts will be needed.
To move trauma care, stakeholders should prioritize early detection, implement individualized treatment plans, ensure equitable access for all communities, and maintain a strong focus on human-centered care. Survivors, clinicians, policymakers, and innovators must collaborate now to advance trauma care. Concrete steps today can create a new standard—one that respects both psychological and biological needs and enables lasting recovery.
Post-Traumatic Stress Disorder (PTSD) - National Institute of Mental Health (NIMH). (n.d.). nih.gov. https://www.nimh.nih.gov/health/statistics/post-traumatic-stress-disorder-ptsd
Klein, Paul (2023). Police turnover is costing Nevada big. Unknown Journal.
McCain, N.L. and Smith, J.C. (1994). Stress and coping in the context of psychoneuroimmunology: a holistic framework for nursing practice and research. Archives of Psychiatric Nursing, 8.
Passos, I. C., Vasconcelos-Moreno, M. P., Costa, L. G., Kunz, M., Brietzke, E., Quevedo, J., Salum, G., Magalhães, P. V., Kapczinski, F., Kauer-Sant'Anna, M. (2015). Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry, 2.
iXpressGenes Appoints John Schmitt as CEO, Announces Nationwide TAI Test Launch. (2024). iXpressGenes. https://www.ixpressgenes.com/news/ixpressgenes-appoints-john-schmitt-as-ceo%2C-announces-nationwide-tai-test-launch
Pokrzywa, L. (2015). Effective Wellness Programs are a Win-Win!. East Coast Risk Management. https://eastcoastriskmanagement.com/effective-wellness-programs-win-win/
.png){kind=small}
